http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 10 Feb 2026 09:00:44 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Creative+Medical+receives+second+WHO+name+designation+for+cell+therapy/25972330.html <p>Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) announced that the World Health Organization has published the proposed International Nonproprietary Name "etaroleucel" for CELZ-101, the company's autologous regulatory T-cell immunotherapy program.</p><p>The WHO published the proposed name in Proposed INN List 134 following expert review during the 80th WHO INN Consultation held March 18-21, 2025. The name is now entering the formal objection period before final confirmation under standard WHO procedures.</p><p>CELZ-101 is designed to induce immune tolerance in autoimmune settings, including Type 1 diabetes in pancreatic islet transplantation contexts. The platform has been validated in cardiovascular and hepatic clinical applications, according to http://www.streetinsider.com/Corporate+News/Creative+Medical+receives+second+WHO+name+designation+for+cell+therapy/25972330.html Tue, 10 Feb 2026 09:00:44 -0500 CELZ http://www.streetinsider.com/FDA/Creative+Medical+receives+second+WHO+name+designation+for+cell+therapy/25972330.html <p>Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) announced that the World Health Organization has published the proposed International Nonproprietary Name "etaroleucel" for CELZ-101, the company's autologous regulatory T-cell immunotherapy program.</p><p>The WHO published the proposed name in Proposed INN List 134 following expert review during the 80th WHO INN Consultation held March 18-21, 2025. The name is now entering the formal objection period before final confirmation under standard WHO procedures.</p><p>CELZ-101 is designed to induce immune tolerance in autoimmune settings, including Type 1 diabetes in pancreatic islet transplantation contexts. The platform has been validated in cardiovascular and hepatic clinical applications, according to http://www.streetinsider.com/FDA/Creative+Medical+receives+second+WHO+name+designation+for+cell+therapy/25972330.html Tue, 10 Feb 2026 09:00:44 -0500 CELZ http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0500 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Corporate+News/Creative+Medical+reports+positive+interim+data+for+chronic+back+pain+therapy/25842059.html <p>Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) announced positive interim results from its ADAPT clinical trial evaluating CELZ-201 (Olastrocel), a cell therapy for chronic lower back pain associated with degenerative disc disease.</p><p>The 180-day follow-up data showed statistically significant improvements in both functional disability and pain reduction. Patients experienced a mean improvement of 15.3 percentage points in functional disability scores, with approximately 79% achieving clinically meaningful improvement. Pain scores decreased by an average of 3.9 points on a 0-10 scale, with 79% of patients achieving at least a 2-point reduction.</p><p>An independent Data Safety Monitoring Board review confirmed no serious adverse events http://www.streetinsider.com/Corporate+News/Creative+Medical+reports+positive+interim+data+for+chronic+back+pain+therapy/25842059.html Tue, 13 Jan 2026 09:15:40 -0500 CELZ http://www.streetinsider.com/FDA/Creative+Medical+reports+positive+interim+data+for+chronic+back+pain+therapy/25842059.html <p>Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) announced positive interim results from its ADAPT clinical trial evaluating CELZ-201 (Olastrocel), a cell therapy for chronic lower back pain associated with degenerative disc disease.</p><p>The 180-day follow-up data showed statistically significant improvements in both functional disability and pain reduction. Patients experienced a mean improvement of 15.3 percentage points in functional disability scores, with approximately 79% achieving clinically meaningful improvement. Pain scores decreased by an average of 3.9 points on a 0-10 scale, with 79% of patients achieving at least a 2-point reduction.</p><p>An independent Data Safety Monitoring Board review confirmed no serious adverse events http://www.streetinsider.com/FDA/Creative+Medical+reports+positive+interim+data+for+chronic+back+pain+therapy/25842059.html Tue, 13 Jan 2026 09:15:40 -0500 CELZ http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Reaches+Major+Clinical+Inflection+Point+with+Positive+Interim+Data+from+ADAPT+Trial+and+CELZ-201+%28Olastrocel%29+in+the+Treatment+of+Chronic+Lower+Back+Pain/25842053.html <p>PHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company’s proprietary perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease.</p> <p>The study produced statistically significant, clinically meaningful improvements in both functional disability (ODI%) and pain at primary trial end point, confirming durable human efficacy alongside an excellent safety profile.</p> <p>The announcement of this data follows a http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Reaches+Major+Clinical+Inflection+Point+with+Positive+Interim+Data+from+ADAPT+Trial+and+CELZ-201+%28Olastrocel%29+in+the+Treatment+of+Chronic+Lower+Back+Pain/25842053.html Tue, 13 Jan 2026 09:15:00 -0500 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Reaches+Major+Clinical+Inflection+Point+with+Positive+Interim+Data+from+ADAPT+Trial+and+CELZ-201+%28Olastrocel%29+in+the+Treatment+of+Chronic+Lower+Back+Pain/25842053.html <p>PHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company’s proprietary perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease.</p> <p>The study produced statistically significant, clinically meaningful improvements in both functional disability (ODI%) and pain at primary trial end point, confirming durable human efficacy alongside an excellent safety profile.</p> <p>The announcement of this data follows a http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Reaches+Major+Clinical+Inflection+Point+with+Positive+Interim+Data+from+ADAPT+Trial+and+CELZ-201+%28Olastrocel%29+in+the+Treatment+of+Chronic+Lower+Back+Pain/25842053.html Tue, 13 Jan 2026 09:15:00 -0500 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Reaches+Major+Clinical+Inflection+Point+with+Positive+Interim+Data+from+ADAPT+Trial+and+CELZ-201+%28Olastrocel%29+in+the+Treatment+of+Chronic+Lower+Back+Pain/25842053.html <p>PHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company’s proprietary perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease.</p> <p>The study produced statistically significant, clinically meaningful improvements in both functional disability (ODI%) and pain at primary trial end point, confirming durable human efficacy alongside an excellent safety profile.</p> <p>The announcement of this data follows a http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Reaches+Major+Clinical+Inflection+Point+with+Positive+Interim+Data+from+ADAPT+Trial+and+CELZ-201+%28Olastrocel%29+in+the+Treatment+of+Chronic+Lower+Back+Pain/25842053.html Tue, 13 Jan 2026 09:15:00 -0500 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Reaches+Major+Clinical+Inflection+Point+with+Positive+Interim+Data+from+ADAPT+Trial+and+CELZ-201+%28Olastrocel%29+in+the+Treatment+of+Chronic+Lower+Back+Pain/25842053.html <p>PHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company’s proprietary perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease.</p> <p>The study produced statistically significant, clinically meaningful improvements in both functional disability (ODI%) and pain at primary trial end point, confirming durable human efficacy alongside an excellent safety profile.</p> <p>The announcement of this data follows a http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Reaches+Major+Clinical+Inflection+Point+with+Positive+Interim+Data+from+ADAPT+Trial+and+CELZ-201+%28Olastrocel%29+in+the+Treatment+of+Chronic+Lower+Back+Pain/25842053.html Tue, 13 Jan 2026 09:15:00 -0500 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Reaches+Major+Clinical+Inflection+Point+with+Positive+Interim+Data+from+ADAPT+Trial+and+CELZ-201+%28Olastrocel%29+in+the+Treatment+of+Chronic+Lower+Back+Pain/25842053.html <p>PHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company’s proprietary perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease.</p> <p>The study produced statistically significant, clinically meaningful improvements in both functional disability (ODI%) and pain at primary trial end point, confirming durable human efficacy alongside an excellent safety profile.</p> <p>The announcement of this data follows a http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Reaches+Major+Clinical+Inflection+Point+with+Positive+Interim+Data+from+ADAPT+Trial+and+CELZ-201+%28Olastrocel%29+in+the+Treatment+of+Chronic+Lower+Back+Pain/25842053.html Tue, 13 Jan 2026 09:15:00 -0500 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209